{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T11:40:28Z","timestamp":1776339628284,"version":"3.51.2"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:00:00Z","timestamp":1776297600000},"content-version":"vor","delay-in-days":37,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"DOI":"10.1186\/s12888-026-07905-5","type":"journal-article","created":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T05:35:16Z","timestamp":1773120916000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["First case of schizophrenia and OCD in TK2-related mitochondrial DNA depletion myopathy: a case report"],"prefix":"10.1186","volume":"26","author":[{"given":"Shu Hui","family":"Ngoh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alakananda","family":"Gudi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,10]]},"reference":[{"key":"7905_CR1","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1038\/sj.mp.4001511","volume":"9","author":"S Prabakaran","year":"2004","unstructured":"Prabakaran S, Swatton JE, Ryan MM, Huffaker SJ, Huang J-J, Griffin JL, et al. Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress. Mol Psychiatry. 2004;9:684\u201397. https:\/\/doi.org\/10.1038\/sj.mp.4001511.","journal-title":"Mol Psychiatry"},{"key":"7905_CR2","doi-asserted-by":"publisher","first-page":"8416763","DOI":"10.1155\/2017\/8416763","volume":"2017","author":"G Pizzino","year":"2017","unstructured":"Pizzino G, Irrera N, Cucinotta M, Pallio G, Mannino F, Arcoraci V, et al. Oxidative stress: harms and benefits for human health. Oxidative Med Cell Longev. 2017;2017:8416763. https:\/\/doi.org\/10.1155\/2017\/8416763.","journal-title":"Oxidative Med Cell Longev"},{"key":"7905_CR3","doi-asserted-by":"publisher","first-page":"703452","DOI":"10.3389\/fpsyt.2021.703452","volume":"12","author":"AJ Murray","year":"2021","unstructured":"Murray AJ, Rogers JC, Katshu MZUH, Liddle PF, Upthegrove R. Oxidative stress and the pathophysiology and symptom profile of schizophrenia spectrum disorders. Front Psychiatry. 2021;12:703452. https:\/\/doi.org\/10.3389\/fpsyt.2021.703452.","journal-title":"Front Psychiatry"},{"key":"7905_CR4","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.schres.2019.09.007","volume":"217","author":"ST Chan","year":"2020","unstructured":"Chan ST, McCarthy MJ, Vawter MP. Psychiatric drugs impact mitochondrial function in brain and other tissues. Schizophr Res. 2020;217:136\u201347. https:\/\/doi.org\/10.1016\/j.schres.2019.09.007.","journal-title":"Schizophr Res"},{"key":"7905_CR5","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1002\/jimd.12196","volume":"43","author":"MC De Vries","year":"2020","unstructured":"De Vries MC, Brown DA, Allen ME, Bindoff L, Gorman GS, Karaa A, et al. Safety of drug use in patients with a primary mitochondrial disease: an international Delphi-based consensus. J Inherit Metab Dis. 2020;43:800\u201318. https:\/\/doi.org\/10.1002\/jimd.12196.","journal-title":"J Inherit Metab Dis"},{"key":"7905_CR6","doi-asserted-by":"publisher","first-page":"459","DOI":"10.34172\/PS.2023.12","volume":"29","author":"A Arjmand","year":"2023","unstructured":"Arjmand A, Azizi Javan E, Shahraki J, Shaboustani R, Seydi E, Pourahmad J. Mitochondrial transplantation attenuates toxicity in human lymphocytes caused by clozapine and Risperidone. Pharm Sci. 2023;29:459\u201365. https:\/\/doi.org\/10.34172\/PS.2023.12.","journal-title":"Pharm Sci"},{"key":"7905_CR7","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1038\/s41386-025-02219-8","volume":"50","author":"E Jetsonen","year":"2025","unstructured":"Jetsonen E, Didio G, Suleymanova I, Teino I, Castr\u00e9n E, Umemori J. Chronic treatment with Fluoxetine regulates mitochondrial features and plasticity-associated transcriptomic pathways in parvalbumin-positive interneurons of prefrontal cortex. Neuropsychopharmacol. 2025;50:1864\u201374. https:\/\/doi.org\/10.1038\/s41386-025-02219-8.","journal-title":"Neuropsychopharmacol"},{"key":"7905_CR8","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.toxlet.2016.07.001","volume":"258","author":"MR De Oliveira","year":"2016","unstructured":"De Oliveira MR. Fluoxetine and the mitochondria: A review of the toxicological aspects. Toxicol Lett. 2016;258:185\u201391. https:\/\/doi.org\/10.1016\/j.toxlet.2016.07.001.","journal-title":"Toxicol Lett"},{"key":"7905_CR9","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/j.biopsych.2017.11.018","volume":"83","author":"L Pei","year":"2018","unstructured":"Pei L, Wallace DC. Mitochondrial etiology of neuropsychiatric disorders. Biol Psychiatry. 2018;83:722\u201330. https:\/\/doi.org\/10.1016\/j.biopsych.2017.11.018.","journal-title":"Biol Psychiatry"},{"key":"7905_CR10","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/978-90-481-2813-6_10","volume-title":"Inherited neuromuscular diseases","author":"S DiMauro","year":"2009","unstructured":"DiMauro S, Hirano M. Pathogenesis and treatment of mitochondrial disorders. In: Espin\u00f3s C, Felipo V, Palau F, editors. Inherited neuromuscular diseases. Volume 652. Dordrecht: Springer Netherlands; 2009. pp. 139\u201370. https:\/\/doi.org\/10.1007\/978-90-481-2813-6_10."},{"key":"7905_CR11","doi-asserted-by":"publisher","first-page":"8971","DOI":"10.1021\/acsomega.8b01376","volume":"3","author":"L Wang","year":"2018","unstructured":"Wang L, Zhang L, Sun R, Eriksson S. Negative cooperative binding of thymidine, ordered substrate binding, and product release of human mitochondrial thymidine kinase 2 explain its complex kinetic properties and physiological functions. ACS Omega. 2018;3:8971\u20139. https:\/\/doi.org\/10.1021\/acsomega.8b01376.","journal-title":"ACS Omega"},{"key":"7905_CR12","doi-asserted-by":"publisher","first-page":"2841","DOI":"10.1093\/brain\/awn236","volume":"131","author":"A Gotz","year":"2008","unstructured":"Gotz A, Isohanni P, Pihko H, Paetau A, Herva R, Saarenpaa-Heikkila O, et al. Thymidine kinase 2 defects can cause multi-tissue MtDNA depletion syndrome. Brain. 2008;131:2841\u201350. https:\/\/doi.org\/10.1093\/brain\/awn236.","journal-title":"Brain"},{"key":"7905_CR13","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1093\/hmg\/ddq043","volume":"19","author":"S Bartesaghi","year":"2010","unstructured":"Bartesaghi S, Betts-Henderson J, Cain K, Dinsdale D, Zhou X, Karlsson A, et al. Loss of thymidine kinase 2 alters neuronal bioenergetics and leads to neurodegeneration. Hum Mol Genet. 2010;19:1669\u201377. https:\/\/doi.org\/10.1093\/hmg\/ddq043.","journal-title":"Hum Mol Genet"},{"key":"7905_CR14","doi-asserted-by":"publisher","first-page":"e213373","DOI":"10.1212\/WNL.0000000000213373","volume":"104","author":"L Bergonzini","year":"2025","unstructured":"Bergonzini L, Carli S, Pelle S, Pettenuzzo I, Bonetti S, Santi E, et al. Infantile TK2 deficiency causing mitochondrial encephalomyopathy with migrating focal seizures. Neurology. 2025;104:e213373. https:\/\/doi.org\/10.1212\/WNL.0000000000213373.","journal-title":"Neurology"},{"key":"7905_CR15","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1001\/archneur.63.8.1122","volume":"63","author":"M Oskoui","year":"2006","unstructured":"Oskoui M, Davidzon G, Pascual J, Erazo R, Gurgel-Giannetti J, Krishna S, et al. Clinical spectrum of mitochondrial DNA depletion due to mutations in the thymidine kinase 2 gene. Arch Neurol. 2006;63:1122. https:\/\/doi.org\/10.1001\/archneur.63.8.1122.","journal-title":"Arch Neurol"},{"key":"7905_CR16","doi-asserted-by":"publisher","first-page":"276","DOI":"10.3390\/cells14040276","volume":"14","author":"H-M Yang","year":"2025","unstructured":"Yang H-M. Mitochondrial dysfunction in neurodegenerative diseases. Cells. 2025;14:276. https:\/\/doi.org\/10.3390\/cells14040276.","journal-title":"Cells"},{"key":"7905_CR17","doi-asserted-by":"publisher","first-page":"122257","DOI":"10.1016\/j.lfs.2023.122257","volume":"334","author":"EE Alshial","year":"2023","unstructured":"Alshial EE, Abdulghaney MI, Wadan A-HS, Abdellatif MA, Ramadan NE, Suleiman AM, et al. Mitochondrial dysfunction and neurological disorders: A narrative review and treatment overview. Life Sci. 2023;334:122257. https:\/\/doi.org\/10.1016\/j.lfs.2023.122257.","journal-title":"Life Sci"},{"key":"7905_CR18","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1176\/appi.neuropsych.11110345","volume":"24","author":"RE Anglin","year":"2012","unstructured":"Anglin RE, Tarnopolsky MA, Mazurek MF, Rosebush PI. The psychiatric presentation of mitochondrial disorders in adults. JNP. 2012;24:394\u2013409. https:\/\/doi.org\/10.1176\/appi.neuropsych.11110345.","journal-title":"JNP"},{"key":"7905_CR19","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41392-024-02044-3","volume":"10","author":"H Wen","year":"2025","unstructured":"Wen H, Deng H, Li B, Chen J, Zhu J, Zhang X, et al. Mitochondrial diseases: from molecular mechanisms to therapeutic advances. Sig Transduct Target Ther. 2025;10:9. https:\/\/doi.org\/10.1038\/s41392-024-02044-3.","journal-title":"Sig Transduct Target Ther"},{"key":"7905_CR20","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.schres.2007.06.018","volume":"97","author":"A Thorup","year":"2007","unstructured":"Thorup A, Petersen L, Jeppesen P, Nordentoft M. Frequency and predictive values of first rank symptoms at baseline among 362 young adult patients with first-episode schizophrenia. Schizophr Res. 2007;97:60\u20137. https:\/\/doi.org\/10.1016\/j.schres.2007.06.018.","journal-title":"Schizophr Res"},{"key":"7905_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1176\/appi.psy.47.1.1","volume":"47","author":"O Fattal","year":"2006","unstructured":"Fattal O, Budur K, Vaughan AJ, Franco K. Review of the literature on major mental disorders in adult patients with mitochondrial diseases. Psychosomatics. 2006;47:1\u20137. https:\/\/doi.org\/10.1176\/appi.psy.47.1.1.","journal-title":"Psychosomatics"},{"key":"7905_CR22","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.schres.2020.09.003","volume":"223","author":"BS Pruett","year":"2020","unstructured":"Pruett BS, Meador-Woodruff JH. Evidence for altered energy metabolism, increased lactate, and decreased pH in schizophrenia brain: A focused review and meta-analysis of human postmortem and magnetic resonance spectroscopy studies. Schizophr Res. 2020;223:29\u201342. https:\/\/doi.org\/10.1016\/j.schres.2020.09.003.","journal-title":"Schizophr Res"},{"key":"7905_CR23","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.neubiorev.2014.11.005","volume":"48","author":"A Rajasekaran","year":"2015","unstructured":"Rajasekaran A, Venkatasubramanian G, Berk M, Debnath M. Mitochondrial dysfunction in schizophrenia: Pathways, mechanisms and implications. Neurosci Biobehavioral Reviews. 2015;48:10\u201321. https:\/\/doi.org\/10.1016\/j.neubiorev.2014.11.005.","journal-title":"Neurosci Biobehavioral Reviews"},{"key":"7905_CR24","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.ijdevneu.2010.08.007","volume":"29","author":"HB Clay","year":"2011","unstructured":"Clay HB, Daws S, Konradi C. Mitochondrial dysfunction and pathology in bipolar disorder and schizophrenia. Intl J Devlp Neurosci. 2011;29:311\u201324. https:\/\/doi.org\/10.1016\/j.ijdevneu.2010.08.007.","journal-title":"Intl J Devlp Neurosci"},{"key":"7905_CR25","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1176\/ajp.156.6.869","volume":"156","author":"S Nyberg","year":"1999","unstructured":"Nyberg S, Eriksson B, Oxenstierna G, Halldin C, Farde L. Suggested minimal effective dose of Risperidone based on PET-Measured D2 and 5-HT2A receptor occupancy in schizophrenic patients. AJP. 1999;156:869\u201375. https:\/\/doi.org\/10.1176\/ajp.156.6.869.","journal-title":"AJP"},{"key":"7905_CR26","doi-asserted-by":"publisher","first-page":"7991","DOI":"10.3390\/ijms24097991","volume":"24","author":"I Fiz\u00edkov\u00e1","year":"2023","unstructured":"Fiz\u00edkov\u00e1 I, Draga\u0161ek J, Ra\u010day P. Mitochondrial Dysfunction, altered mitochondrial Oxygen, and energy metabolism associated with the pathogenesis of schizophrenia. IJMS. 2023;24:7991. https:\/\/doi.org\/10.3390\/ijms24097991.","journal-title":"IJMS"},{"key":"7905_CR27","doi-asserted-by":"publisher","first-page":"710","DOI":"10.2174\/1570159X16666180813155017","volume":"17","author":"A Del Casale","year":"2019","unstructured":"Del Casale A, Sorice S, Padovano A, Simmaco M, Ferracuti S, Lamis DA, et al. Psychopharmacological treatment of Obsessive-Compulsive disorder (OCD). CN. 2019;17:710\u201336. https:\/\/doi.org\/10.2174\/1570159X16666180813155017.","journal-title":"CN"},{"key":"7905_CR28","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.bbr.2005.06.012","volume":"165","author":"H Einat","year":"2005","unstructured":"Einat H, Yuan P, Manji H. Increased anxiety-like behaviors and mitochondrial dysfunction in mice with targeted mutation of the Bcl-2 gene: further support for the involvement of mitochondrial function in anxiety disorders. Behav Brain Res. 2005;165:172\u201380. https:\/\/doi.org\/10.1016\/j.bbr.2005.06.012.","journal-title":"Behav Brain Res"},{"key":"7905_CR29","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/nature04250","volume":"438","author":"I Hovatta","year":"2005","unstructured":"Hovatta I, Tennant RS, Helton R, Marr RA, Singer O, Redwine JM, et al. Glyoxalase 1 and glutathione reductase 1 regulate anxiety in mice. Nature. 2005;438:662\u20136. https:\/\/doi.org\/10.1038\/nature04250.","journal-title":"Nature"},{"key":"7905_CR30","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1002\/pmic.201500242","volume":"16","author":"KO Schubert","year":"2016","unstructured":"Schubert KO, F\u00f6cking M, Wynne K, Cotter DR. Proteome and pathway effects of chronic haloperidol treatment in mouse hippocampus. Proteomics. 2016;16:532\u20138. https:\/\/doi.org\/10.1002\/pmic.201500242.","journal-title":"Proteomics"},{"key":"7905_CR31","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1002\/pmic.201300466","volume":"14","author":"LA Farrelly","year":"2014","unstructured":"Farrelly LA, Dicker P, Wynne K, English J, Cagney G, F\u00f6cking M, et al. Adolescent Risperidone treatment alters protein expression associated with protein trafficking and cellular metabolism in the adult rat prefrontal cortex. Proteomics. 2014;14:1574\u20138. https:\/\/doi.org\/10.1002\/pmic.201300466.","journal-title":"Proteomics"},{"key":"7905_CR32","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.euroneuro.2018.01.004","volume":"28","author":"G Scaini","year":"2018","unstructured":"Scaini G, Quevedo J, Velligan D, Roberts DL, Raventos H, Walss-Bass C. Second generation antipsychotic-induced mitochondrial alterations: implications for increased risk of metabolic syndrome in patients with schizophrenia. Eur Neuropsychopharmacol. 2018;28:369\u201380. https:\/\/doi.org\/10.1016\/j.euroneuro.2018.01.004.","journal-title":"Eur Neuropsychopharmacol"},{"key":"7905_CR33","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1097\/JCP.0b013e318054753e","volume":"27","author":"J Casademont","year":"2007","unstructured":"Casademont J, Garrabou G, Mir\u00f3 \u00d2, L\u00f3pez S, Pons A, Bernardo M, et al. Neuroleptic treatment effect on mitochondrial electron transport chain: peripheral blood mononuclear cells analysis in psychotic patients. J Clin Psychopharmacol. 2007;27:284\u20138. https:\/\/doi.org\/10.1097\/JCP.0b013e318054753e.","journal-title":"J Clin Psychopharmacol"},{"key":"7905_CR34","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1007\/s00210-019-01665-8","volume":"392","author":"T Cik\u00e1nkov\u00e1","year":"2019","unstructured":"Cik\u00e1nkov\u00e1 T, Fi\u0161ar Z, Bakhouche Y, \u013dupt\u00e1k M, Hroudov\u00e1 J. In vitro effects of antipsychotics on mitochondrial respiration. Naunyn-Schmiedeberg\u2019s Arch Pharmacol. 2019;392:1209\u201323. https:\/\/doi.org\/10.1007\/s00210-019-01665-8.","journal-title":"Naunyn-Schmiedeberg\u2019s Arch Pharmacol"},{"key":"7905_CR35","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/S0022-3565(24)36399-2","volume":"280","author":"JA Prince","year":"1997","unstructured":"Prince JA, Yassin MS, Oreland L. Neuroleptic-induced mitochondrial enzyme alterations in the rat brain. J Pharmacol Exp Ther. 1997;280:261\u20137.","journal-title":"J Pharmacol Exp Ther"},{"key":"7905_CR36","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1007\/s12031-018-1165-4","volume":"66","author":"Z-L Bai","year":"2018","unstructured":"Bai Z-L, Li X-S, Chen G-Y, Du Y, Wei Z-X, Chen X, et al. Serum oxidative stress marker levels in unmedicated and medicated patients with schizophrenia. J Mol Neurosci. 2018;66:428\u201336. https:\/\/doi.org\/10.1007\/s12031-018-1165-4.","journal-title":"J Mol Neurosci"},{"key":"7905_CR37","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.neulet.2010.10.037","volume":"487","author":"FR Agostinho","year":"2011","unstructured":"Agostinho FR, R\u00e9us GZ, Stringari RB, Ribeiro KF, Ferraro AK, Benedet J, et al. Treatment with olanzapine, Fluoxetine and olanzapine\/fluoxetine alters citrate synthase activity in rat brain. Neurosci Lett. 2011;487:278\u201381. https:\/\/doi.org\/10.1016\/j.neulet.2010.10.037.","journal-title":"Neurosci Lett"},{"key":"7905_CR38","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.brainres.2017.01.025","volume":"1659","author":"D Filipovi\u0107","year":"2017","unstructured":"Filipovi\u0107 D, Costina V, Peri\u0107 I, Stanisavljevi\u0107 A, Findeisen P. Chronic Fluoxetine treatment directs energy metabolism towards the citric acid cycle and oxidative phosphorylation in rat hippocampal nonsynaptic mitochondria. Brain Res. 2017;1659:41\u201354. https:\/\/doi.org\/10.1016\/j.brainres.2017.01.025.","journal-title":"Brain Res"},{"key":"7905_CR39","doi-asserted-by":"publisher","unstructured":"Magalh\u00e3es PVS, Dean O, Andreazza AC, Berk M, Kapczinski F. Antioxidant treatments for schizophrenia. Cochrane Database Syst Rev. 2016;2016. https:\/\/doi.org\/10.1002\/14651858.CD008919.pub2.","DOI":"10.1002\/14651858.CD008919.pub2"},{"key":"7905_CR40","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1080\/1028415X.2018.1556481","volume":"23","author":"\u00c1 Maguire","year":"2020","unstructured":"Maguire \u00c1, Hargreaves A, Gill M. Coenzyme Q10 and neuropsychiatric and neurological disorders: relevance for schizophrenia. Nutr Neurosci. 2020;23:756\u201369. https:\/\/doi.org\/10.1080\/1028415X.2018.1556481.","journal-title":"Nutr Neurosci"},{"key":"7905_CR41","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1007\/s12035-013-8477-8","volume":"48","author":"G Morris","year":"2013","unstructured":"Morris G, Anderson G, Berk M, Maes M. Coenzyme Q10 depletion in medical and neuropsychiatric disorders: potential repercussions and therapeutic implications. Mol Neurobiol. 2013;48:883\u2013903. https:\/\/doi.org\/10.1007\/s12035-013-8477-8.","journal-title":"Mol Neurobiol"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12888-026-07905-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-026-07905-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-026-07905-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T10:41:10Z","timestamp":1776336070000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12888-026-07905-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,10]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["7905"],"URL":"https:\/\/doi.org\/10.1186\/s12888-026-07905-5","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,10]]},"assertion":[{"value":"22 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent for publication has been obtained from the patient for their personal and clinical details to be published in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"323"}}